Skip to main content
. Author manuscript; available in PMC: 2021 Apr 29.
Published in final edited form as: J Med Chem. 2021 Jan 28;64(3):1626–1648. doi: 10.1021/acs.jmedchem.0c01897

Figure 8.

Figure 8.

XD2–149 degrades ZFP91 protein in a proteasome-dependent manner. (A) XD2–149 reduces ZFP91 expression while napabucasin (NP) has no effect. BxPC-3 cells were treated with NP or XD2–149 at the indicated concentrations for 16 h. (B) XD2–149 degrades ZFP91 at 16 and 24 h with no effect at 4 h. Dose-response curves of ZFP91 degradation by XD2–149 are presented for the 16 and 24 h time-points. (C) The effect of XD2–149 on ZFP91 is proteasome-dependent. BxPC-3 cells were pretreated with 1 μM of the proteasome inhibitor carfilzomib for 1 h followed by XD2–149 or XD2–162 treatment for 16 h. (D) NP does not abolish the effect of XD2–149. BxPC-3 cells were treated with XD2–149 in presence or absence of NP for 16 h. (E) Pomalidomide (POM) induces ZFP91 degradation after 16 h. (F) XD2–149 have no effect on the expression of GSPT. BxPC-3 cells were treated with NP or XD2–149 for 16 h. Immunoblots were quantified using ImageJ and the DC50 values were calculated using GraphPad Prism 8. * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001.